Jacobs Levy Equity Management Inc. Acquires 506,853 Shares of Arcus Biosciences, Inc. $RCUS

Jacobs Levy Equity Management Inc. lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 108.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 972,157 shares of the company's stock after buying an additional 506,853 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.92% of Arcus Biosciences worth $7,631,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. E Fund Management Co. Ltd. bought a new position in Arcus Biosciences in the first quarter valued at about $82,000. Lazard Asset Management LLC boosted its stake in shares of Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after purchasing an additional 6,078 shares in the last quarter. Knott David M Jr acquired a new stake in shares of Arcus Biosciences in the 1st quarter valued at approximately $94,000. Exchange Traded Concepts LLC grew its holdings in shares of Arcus Biosciences by 40.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 13,922 shares of the company's stock valued at $109,000 after purchasing an additional 4,013 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in Arcus Biosciences by 21.3% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,381 shares of the company's stock worth $121,000 after purchasing an additional 2,700 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RCUS. Wells Fargo & Company dropped their price objective on shares of Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.14.

Arcus Biosciences Stock Up 5.7%

NYSE:RCUS opened at $12.22 on Monday. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.50 and a quick ratio of 4.50. The company has a market cap of $1.30 billion, a PE ratio of -3.85 and a beta of 0.82. The firm's 50 day simple moving average is $9.71 and its 200 day simple moving average is $9.11.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. The firm had revenue of $160.00 million during the quarter, compared to analysts' expectations of $32.86 million. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The company's revenue was up 310.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.02) EPS. On average, research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.